These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35460156)

  • 1. A case of twins affected by psoriasis, psoriatic arthritis and autism: Five years of efficacious and safe treatment with Secukinumab.
    Bernardini N; Skroza N; Marraffa F; Prevete E; Mambrin A; Proietti I; Tolino E; Caviglia M; Di Guardo A; Rossi G; Volpe S; Bersani G; Potenza C
    Dermatol Ther; 2022 Jul; 35(7):e15533. PubMed ID: 35460156
    [No Abstract]   [Full Text] [Related]  

  • 2. A review of secukinumab in psoriasis treatment.
    Berg SH; Balogh EA; Ghamrawi RI; Feldman SR
    Immunotherapy; 2021 Feb; 13(3):201-216. PubMed ID: 33203276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.
    Elewski BE; Baddley JW; Deodhar AA; Magrey M; Rich PA; Soriano ER; Soung J; Bao W; Keininger D; Marfo K; Patekar M; Sharma A; Shete A; Lebwohl MG
    JAMA Dermatol; 2021 Jan; 157(1):43-51. PubMed ID: 33001147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paradoxical Pustular Psoriasis in a Patient With Psoriatic Arthritis on Secukinumab Treatment.
    Abbruzzese A; Venerito V; Lopalco G; Fornaro M; Giannotta M; Iannone F
    J Clin Rheumatol; 2020 Sep; 26(6):e208-e209. PubMed ID: 31192857
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
    Deodhar A; Mease PJ; McInnes IB; Baraliakos X; Reich K; Blauvelt A; Leonardi C; Porter B; Das Gupta A; Widmer A; Pricop L; Fox T
    Arthritis Res Ther; 2019 May; 21(1):111. PubMed ID: 31046809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secukinumab in the Treatment of Psoriasis and Psoriatic Arthritis: A Review of the Literature.
    Abrouk M; Gandy J; Nakamura M; Lee K; Brodsky M; Singh R; Zhu H; Farahnik B; Bhutani T; Koo J
    Skin Therapy Lett; 2017 Jul; 22(4):1-6. PubMed ID: 28732152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Injection Site Reactions to Biologic Agents Used in Psoriasis and Psoriatic Arthritis.
    Henderson Berg MH; Carrasco D
    J Drugs Dermatol; 2017 Jul; 16(7):695-698. PubMed ID: 28697222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secukinumab retreatment associated psoriasis flare with pustules.
    El-Komy M; Amer M; Mostafa A; ElKalioby M
    J Dermatolog Treat; 2022 Mar; 33(2):1107-1110. PubMed ID: 32538223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
    Gottlieb AB; Deodhar A; Mcinnes IB; Baraliakos X; Reich K; Schreiber S; Bao W; Marfo K; Richards HB; Pricop L; Shete A; Trivedi V; Keefe D; Papavassilis CC; Jagiello P; Papanastasiou P; Mease PJ; Lebwohl M
    Acta Derm Venereol; 2022 Apr; 102():adv00698. PubMed ID: 35146532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful secukinumab treatment of erythrodermic psoriasis and psoriatic arthritis concomitant with severe noninfectious uveitis: a case report.
    Lu J; Tang S; Yu N; Yi X; Li Y
    J Int Med Res; 2020 Nov; 48(11):300060520969494. PubMed ID: 33161790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
    Canavan TN; Elmets CA; Cantrell WL; Evans JM; Elewski BE
    Am J Clin Dermatol; 2016 Feb; 17(1):33-47. PubMed ID: 26649440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of secukinumab in psoriasis and psoriatic arthritis: A retrospective multicentre study.
    Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Galán-Gutierrez M; Martinez-Pilar L
    Med Clin (Barc); 2020 May; 154(9):370-371. PubMed ID: 30717997
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease.
    Reich K; Warren RB; Coates LC; Di Comite G
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1161-1173. PubMed ID: 31785165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.
    Kiltz U; Sfikakis PP; Gaffney K; Sator PG; von Kiedrowski R; Bounas A; Gullick N; Conrad C; Rigopoulos D; Lespessailles E; Romanelli M; Ghislain PD; Brandt-Jürgens J; Rashkov R; Aassi M; Orsenigo R; Perella C; Pournara E; Gathmann S; Jagiello P; Veit J; Augustin M
    Adv Ther; 2020 Jun; 37(6):2865-2883. PubMed ID: 32378070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New onset inflammatory bowel disease in patient treated with secukinumab: Case report and review of literature.
    Ali AK; Torosian A; Porter C; Bloomfeld RS; Feldman SR
    Dermatol Ther; 2021 Nov; 34(6):e15151. PubMed ID: 34609037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggravation of discoid lupus erythematosus in a patient with psoriasis and psoriatic arthritis during treatment of secukinumab: A case report and review of literature.
    Hsieh CY; Tsai TF
    Lupus; 2022 Jun; 31(7):891-894. PubMed ID: 35438595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible autoimmune hemolytic anemia induced by secukinumab: a case report.
    Rahman PA; Kalim H; Prawitasari S; Raharjo FM
    Pan Afr Med J; 2022; 41():41. PubMed ID: 35317476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory bowel disease new-onset during secukinumab therapy: real-world data from a tertiary center.
    Ojeda Gómez A; Madero Velázquez L; Buendía Sanchez L; Pascual Sánchez I; Pérez Rabasco E; García Monsalve A; González Ferrández JA; García Sepulcre MF
    Rev Esp Enferm Dig; 2021 Dec; 113(12):858-859. PubMed ID: 34696593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis.
    Reich K; Baraliakos X; Coates LC; Elewski B; Bao W; Kasparek T; Gaillez C; Pournara E; Aassi M; Perella C; Gottlieb AB
    Br J Dermatol; 2022 Sep; 187(3):438-441. PubMed ID: 35257363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis.
    van de Kerkhof PCM
    Br J Dermatol; 2021 Nov; 185(5):879. PubMed ID: 34402525
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.